Epcoritimab Combo Could Be New Standard for Some FLs

Patients with relapsed or refractory follicular lymphoma have few treatment options—with a rituximab–lenalidomide (R2) pairing considered the only alternative to immunochemotherapy. But data from the pivotal phase III EPCORE LF-1 trial show that a three-drug combination of epcoritimab plus R2 can reduce the risk of disease progression and death by 79% compared with R2 alone.